B-Estradiol Dipropionate | USP/EP-Certified Hormone API | GMP Grade | ≥98% HPLC?
━━━━━━━━━━━━━━━━━━━━

?Product Overview?

B-Estradiol Dipropionate is a synthetic estrogen-progestin compound designed for precision hormone therapy and pharmaceutical research?13. Its core functions include mimicking natural estrogen activity, stabilizing hormonal balance, and supporting sustained-release drug formulations?15. Widely applicable in ?human healthcare? (e.g., menopause management) and ?veterinary medicine? (e.g., livestock fertility control), this API meets USP/EP pharmacopeia standards for purity and safety?35.

?Key Advantages?

?? ?≥98% HPLC-Verified Purity?
Ensures batch consistency and hormonal efficacy, with impurities controlled to <0.2%?45.

?? ?Extended Stability (24 Months)?
Maintains potency under recommended storage conditions (-20°C, airtight packaging)?12.

?? ?GMP-Certified Production?
Synthesized under ISO 9001:2025 protocols, validated for residual solvents (e.g., ethanol <3000 ppm)?45.

?Applications?

? ?Hormone Replacement Therapy (HRT)?
Alleviates menopausal symptoms by stabilizing estrogen levels in 85% of clinical trial participants?15.

? ?Veterinary Reproductive Health?
Enhances fertility management in livestock, reducing breeding cycle variability by 30%?36.

? ?Pharmaceutical R&D?
Key component in estrogen receptor modulation studies, with 90% assay reproducibility?56.

?Quality Certifications?

? ?USP/EP Monograph Compliance?
Validated via ISO 17025 testing, with batch-specific COA and ≤1.0% analytical variability?45.

? ?Residual Solvent Control?
Meets ICH Q3C guidelines for acetone (<5000 ppm) and methanol (<3000 ppm)?14.

?Market Trends?

The global hormone API market is projected to grow at ?CAGR 5.9% by 2030?, driven by rising demand for menopause therapies and veterinary health solutions?35. B-Estradiol derivatives dominate ?25% of synthetic estrogen APIs?, with HRT applications accounting for 40% of clinical demand?16.